Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 not yet has established its treatment, but convalescent plasma has been expected to increase survival rates as in the case with other emerging viral infections. We describe two cases of COVID-19 treated with convalescent plasma infusion. Both patients presented severe pneumonia with acute respiratory distress syndrome and showed a favorable outcome after the use of convalescent plasma in addition to systemic corticosteroid. To our knowledge, this is the first report of the use of convalescent plasma therapy for COVID-19 in Korea.

Keywords: Coronavirus; SARS-CoV-2; COVID-19; Treatment; Convalescent Plasma

INTRODUCTION

An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, which began in Wuhan, China, has emerged as a primary concern all over the world. The World Health Organization announced the risk assessment of coronavirus disease 2019 (COVID-19) as very high at the global level, and fatal cases are rapidly increasing. By March 24, 2020, more than 9,000 people were infected, and 126 people died, in South Korea. Without specific treatments for the virus, treatment options are being studied in addition to supportive care. Evidence shows that the use of convalescent plasma to treat emerging viral infections, including SARS, Middle East respiratory syndrome (MERS), Ebola virus disease or avian flu, can improve survival rates in patients whose condition worsens even with conventional treatment. However, the safety and efficacy of convalescent plasma treatment in COVID-19 have not been known. Here, we report two cases of severe COVID-19
patients presenting acute respiratory distress syndrome (ARDS), who showed a favorable clinical course after the convalescent plasma infusion. This is the first report of the use of convalescent plasma to treat cases of SARS-CoV-2 infection in Korea.

**CASE DESCRIPTION**

**Case 1**
A previously healthy 71-year-old man visited the Community Health Center on February 22, presenting 12 days of fever and cough. He underwent an examination of SARS-CoV-2 via real-time reverse transcription polymerase chain reaction (rRT-PCR) and diagnosed as COVID-19. He admitted to the local public medical center and 400 mg of hydroxychloroquine was started daily. A chest radiograph obtained on day 2 showed mild opacities in the right lower lung, lopinavir/ritonavir 400 mg/100 mg twice daily was added. However, on day 3, oxygen demand increased, so he transferred to the tertiary-care hospital.

At the time of arrival, the patient had no subjective dyspnea under 4 L/min oxygen flow via nasal cannula, but the respiratory rate was over 30 times per minute. Chest radiographs demonstrated rapidly aggravated bilateral infiltration. Routine blood tests found white blood cell (WBC) count at 3.53 × 10^3/µL, with lymphopenia of 0.4 × 10^3/µL. C-reactive protein (CRP) and lactic dehydrogenase (LDH) elevated up to 59.7 mg/L and 814 IU/L. Routine chemistry, electrolyte, and blood coagulation tests revealed no abnormalities except mildly elevated aspartate transaminase. The level of interleukin 6 (IL-6) was increased as 101.3 pg/mL. Serial bacterial culture and polymerase chain reaction (PCR) for other respiratory viruses were all negative.

Intubation and mechanical ventilator care were started according to the management of ARDS. Despite the continuous use of lopinavir/ritonavir, hydroxychloroquine and empirical antibiotics, he remained febrile with aggravated oxygenation profiles and chest images. Laboratory test showed further elevation of CRP (172.6 mg/L), IL-6 (208.2 pg/mL).

On day 9, the arterial blood gas analysis showed PaO_2/FiO_2 of 86, consistent with severe ARDS. Intravenous methylprednisolone (1 mg/kg/day daily) was started. On day 10, convalescent plasma was obtained from a male donor in his 20s who had recovered from COVID-19 for 21 days. He was diagnosed as COVID-19 presenting fever, cough and pneumonia, however, showed complete recovery and didn't have any symptom at the time of plasma donation. He has met the blood donor eligibility criteria for plasma donation, including age, weight, reasonable-sized antecubital veins. Also, allogeneic donor screening tests, defined by enforcement rules of the Blood Management Act in Korea, were acceptable for transfusion. Donor apheresis was performed with Spectra Optia apheresis system (CMNC software; Spectra Optia IDL Tubing set; Terumo BCT, Lakewood, CO, USA), 500 mL of convalescent plasma was collected. Anti-SARS-CoV-2 IgG antibody in plasma was measured by enzyme-linked immunosorbent assay (ELISA) (Novel Coronavirus COVID-19 IgG ELISA kit; Epitope Diagnostics, San Diego, CA, USA) and optical density (OD) ratio for IgG was 0.586 (cut-off value 0.22). The plasma was divided into two doses and administered to the patient at 12 hours interval. Each dose was given over for 1 hour. No adverse reaction occurred after the administration of convalescent plasma.

The fever subsided, and oxygen demand decreased since day 11. The patient’s condition much improved with decreased CRP and IL-6 to normal range (5.7 mg/L and < 1.5 pg/mL).
respectively), and on day 18, PaO\textsubscript{2}/FiO\textsubscript{2} increased up to 300 (Fig. 1). A chest X-ray revealed further resolution of both lung infiltrates (Fig. 2). SARS-CoV-2 was quantified by detection of the RNA-dependent RNA polymerase region of the ORF1b gene on rRT-PCR, the value of cycle threshold (Ct) changed from 24.98 on day 10 to 33.96 on day 20 after plasma infusion (Fig. 1). SARS-CoV-2 was negative after day 26. The patient underwent a tracheostomy and currently, is successfully weaned from the mechanical ventilator.

**Case 2**

A 67-year-old woman with a medical history of hypertension developed fever and myalgia and diagnosed as COVID-19 via SARS-CoV-2 rRT-PCR on March 6. The next day, she was admitted to a local public medical center and received hydroxychloroquine 400 mg once daily and lopinavir/ritonavir 400 mg/100 mg twice daily with empirical antibiotics. However, on day 3, she was transferred to the tertiary-care hospital due to increased oxygen demand and worsening infiltrative shadows in the left lower lung. At that time, her oxygen saturation checked 93% on 4 L/min oxygen flow via nasal cannula with a respiratory rate of 24 times per minute. On day 10, methylprednisolone 12 mg/day was started and convalescent plasma treatment was started. On day 18, PaO\textsubscript{2}/FiO\textsubscript{2} increased up to 300 (Fig. 1). A chest X-ray revealed further resolution of both lung infiltrates (Fig. 2). SARS-CoV-2 was quantified by detection of the RNA-dependent RNA polymerase region of the ORF1b gene on rRT-PCR, the value of cycle threshold (Ct) changed from 24.98 on day 10 to 33.96 on day 20 after plasma infusion (Fig. 1). SARS-CoV-2 was negative after day 26. The patient underwent a tracheostomy and currently, is successfully weaned from the mechanical ventilator.
minute. Routine blood tests showed mild leukocytosis (12.67 × 10^3/µL) with lymphopenia (0.7 × 10^3/µL), elevated CRP, IL-6 and LDH. (131.1 mg/L, 474.7 pg/mL, 344 IU/L, respectively) Routine chemistry, electrolyte, and blood coagulation tests showed no abnormalities. Bacterial cultures and the PCR for other respiratory viruses were all negative.

She received high flow oxygen therapy but bilateral infiltration and oxygenation were deteriorated, so intubation and mechanical ventilator care started on day 4. Intravenous methylprednisolone (0.5 mg/kg/day daily) was also added. She had sustained high fever with rapidly increasing CRP (314 mg/L), WBC (21.79 × 10^3/µL), and persistent lymphopenia (0.5 × 10^3/µL). PaO$_2$/FiO$_2$ fell to 76, consistent with severe ARDS. After applying for the prone position according to the management of ARDS with the use of steroids, chest images and the oxygen demand began to be improved.

On day 6, convalescent plasma was obtained from a male donor in his 20s who had recovered from COVID-19 for 18 days. He was diagnosed as COVID-19 presenting fever, cough and pneumonia however, showed complete recovery and serial PCRs for SARS-CoV-2 were all negative after hospital discharge. Donor screening and plasma collection were performed as mentioned above in the Case 1. OD ratio for IgG was 0.532 and the plasma was administered to the patient in the same way as Case 1. There was no adverse reaction during the plasma transfusion. Leukocytosis and lymphopenia were immediately recovered after convalescent plasma infusion. On day 9, the density of bilateral infiltration on chest X-ray much improved with increased PaO$_2$/FiO$_2$ to 230. The level of CRP and IL-6 also recovered to the normal range (Figs. 3 and 4). SARS-CoV-2 was quantified by rRT-PCR; the value of Ct changed from 20.51 on day 5 to 36.33 on day 9 after plasma infusion (Fig. 3). The patient is successfully extubated and discharged from the hospital on day 24. SARS-CoV-2 was negative after day 20.

**Ethics statement**

This study was approved by the Institutional Review Board (IRB) of Severance Hospital (IRB No. 4-2020-0076) and with participants’ written informed consent. The images are published under agreement of the patients.
DISCUSSION

The study of the therapeutic benefits of plasma transfusion of a cured person from infectious diseases began in the 20th century. As new antibiotics, antiviral agents, and vaccines are developed, administration of convalescent plasma is not a common treatment, but it can be still an important treatment in the absence of specific treatment of new infectious diseases. Over the decades, convalescent plasma has proved its effectiveness as a potential treatment in patients with MERS-CoV, H1N1, H5N1 avian flu, and SARS-CoV. A systemic review and meta-analysis to evaluate the clinical effects of convalescent plasma shows a statistically significant reduction of mortality. In this context, convalescent plasma can be a promising treatment option for severe COVID-19 patients.

As can be seen in the two cases, both received lopinavir/ritonavir and hydroxychloroquine but showed persistent fever, rapidly aggravated hypoxemia and progressive bilateral infiltrations in accordance with the criteria of severe ARDS. After convalescent plasma infusion, the patients showed improved oxygenation and chest X-rays with decreased inflammatory markers and viral loads.

Intravenous methylprednisolone was started just before the convalescent plasma infusion in both cases. We did not use corticosteroids from the beginning as a routine treatment. Current guidelines recommend that systemic corticosteroids should not be given routinely for the treatment of COVID-19 due to the lack of evidence of its clinical efficacy on mortality reduction. However, we decided to start corticosteroids when the patients’ condition rapidly deteriorated to ARDS. Methylprednisolone was administered one day and two days before the plasma infusion in case 1 and case 2, respectively. Serial laboratory and oxygenation parameters showed rapid improvement right after the corticosteroid administration even before the convalescent plasma infusion.

ARDS is partly caused by cytokine storm and host immune responses. Autopsy of patients dying from COVID-19 shows diffuse alveolar damage with exudate and inflammation very similar to those seen in SARS and MERS-CoV infections. Theoretically, systemic corticosteroids may have a role to dampen excessive lung damage due to inflammatory responses. The recent article about risk factors associated with ARDS and death among COVID-19 patients showed...
that treatment with methylprednisolone might be beneficial to reduce the risk of death for
patients developing ARDS.\textsuperscript{11} However, corticosteroids are also thought to inhibit proper immune
responses and viral clearance and delay antibody production.\textsuperscript{12,13}

Convalescent plasma infusion might play a role in the coexistence of benefits and concerns of
corticosteroid use. Antibodies contained in the convalescent plasma will suppress viruses.\textsuperscript{14}
In an animal study, passively transferred antibodies can provide total protection as well as
the maintenance of high levels of antibody titer until the host's immune responses could
be increased to clear the viral infection. Besides, in vivo studies showed that the effects of
neutralizing antibodies were not only limited to viral clearance, but also included acceleration
of infected cell clearance.\textsuperscript{15}

In our cases, the viral load estimated by Ct values showed an increasing trend just before
plasma infusion but began to decrease right after the use of convalescent plasma. Although
improvement of inflammatory marker and oxygenation could be contributed to the combined
use of corticosteroid, decreased viral load of SARS-CoV-2 might mean the effectiveness of
convalescent plasma in the treatment of COVID-2.

Convalescent plasma was administered after 22 days from the onset of symptoms in Case 1,
and 7 days in Case 2, respectively. Because these are not in the early phase of the disease, it is
difficult to determine clearly that the decrease in the viral load shown in both cases is due to
convalescent plasma or natural pathology of COVID-19. Other studies about viral kinetics of
COVID-19 show naturally reducing viral titers after 7–10 days from onset in most patients.\textsuperscript{16,17}
However, Liu and colleagues reported that severe patients requiring intensive care unit
admission due to COVID-19 had high viral load for a longer period than in mild patients.\textsuperscript{16}
Both our cases presented severe ARDS and the viral loads were in increasing trend at the time
of plasma infusion regardless of the date of onset.

In Case 2, the patient showed lymphopenia from day 1, and it persisted even after clinical
improvement with corticosteroid use. When the convalescent plasma was administered on day
6, lymphocyte count immediately rose to normal level (from $0.52 \times 10^3/\mu\text{L}$ to $1.21 \times 10^3/\mu\text{L}$) and
then remained in the normal range. Patients with severe COVID-19 pneumonia and ARDS also
presented with lymphopenia in other studies.\textsuperscript{11} Some authors hypothesized that continuous
and gradual increases in lymphocyte count might be required for immunity against SARS-
CoV-2 infection.\textsuperscript{11} In SARS patients, lymphopenia existed at the onset of illness and persisted
until the recovery period.\textsuperscript{18,19} These findings were consistent with the recovery of lymphocyte
count with clinical improvement of Case 2 after the use of convalescent plasma.

We could not assess neutralizing antibody titers from the convalescent plasma. Plasma with
high neutralizing antibody titers is likely to be available from the patients in the convalescent
phase recovered from severe infection.\textsuperscript{20} To use plasma for treatment, a neutralization test is
suggested as the optimal assay for assessing proper donor or plasma. However, some studies
showed that ELISA IgG correlates well with neutralization titers in MERS cases so that it
might be a suitable screening test for plasma donation.\textsuperscript{20,21} In our cases, donors presented
bilateral pneumonia in the course of COVID-19 and both showed positive results in the ELISA
IgG test for SARS-CoV-2.

There are still limitations for the use of convalescent plasma. Scientific evidence is
insufficient due to the lack of large-scale clinical trials that may be representative of the
target populations. Second, the number of antibodies administered to each patient was not standarized. Finally, convalescent plasma usually proceeds with other treatments, such as antiviral agents and steroids, which can affect the relationship between convalescent plasma and antibody, confounding the results.

Despite the limitations, our cases suggest that convalescent plasma from patients who have recovered from COVID-19 infection might be an additional option to treat patients without causing any severe adverse effects. Also, when used with systemic corticosteroids, we might expect the possibility of reducing excessive inflammatory response by corticosteroids as well as promoting the reduction of viral loads by convalescent plasma simultaneously. Further well-designed studies are needed to demonstrate the efficacy and safety of convalescent plasma transfusion in COVID-19 patients.

REFERENCES

1. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J Infect Dis* 2015;211(1):80-90. [PUBMED] [CROSSREF]

2. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liambruno GM, et al. Convalescent plasma: new evidence for an old therapeutic tool? *Blood Transfus* 2016;14(2):152-7. [PUBMED] [CROSSREF]

3. Burnouf T, Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. *Transfus Apheresis Sci* 2014;51(2):120-5. [PUBMED] [CROSSREF]

4. Public Health England. Treatment of MERS-CoV: information for clinicians. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416. Updated 2017. Accessed February 2, 2020.

5. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis* 2011;52(4):447-56. [PUBMED] [CROSSREF]

6. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin Microbiol Infect* 2004;10(7):676-8. [PUBMED] [CROSSREF]

7. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020;395(10223):473-5. [PUBMED] [CROSSREF]

8. World Health Organization. Geneva: World Health Organization, Jan 28, 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Updated 2020. Accessed February 2, 2020.

9. Hanley B, Lucas SB, Youd E, Swift B, Osborn M. Autopsy in suspected COVID-19 cases. *J Clin Pathol*. Forthcoming 2020. [PUBMED] [CROSSREF]

10. Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe acute respiratory syndrome with convalescent plasma. *Hong Kong Med J* 2003;9(3):199-201. [PUBMED]

11. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med*. Forthcoming 2020. [PUBMED] [CROSSREF]

12. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. *Am J Respir Crit Care Med* 2018;197(6):757-67. [PUBMED] [CROSSREF]
13. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004;31(4):304-9.
PUBMED | CROSSREF

14. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20(4):398-400.
PUBMED | CROSSREF

15. Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 2016;352(6288):1001-4.
PUBMED | CROSSREF

16. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. Forthcoming 2020.
PUBMED | CROSSREF

17. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382(12):1177-9.
PUBMED | CROSSREF

18. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005;202(3):415-24.
PUBMED | CROSSREF

19. Li T, Qiu Z, Zhang L, Han Y, He W, Liu Z, et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J Infect Dis 2004;189(4):648-51.
PUBMED | CROSSREF

20. Choe JG, Perera RA, Park WB, Song KH, Bang JH, Kim ES, et al. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg Infect Dis 2017;23(7):1079-84.
PUBMED | CROSSREF

21. Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther 2018;23(7):617-22.
PUBMED | CROSSREF